CAS: 68377-91-3; Arotinolol Hcl
该化合物是一种制药化合物,主要因其作为非选择性乙醇-肾上腺激素对抗物的作用而得到承认,具有额外的甲型肾上腺阻塞特性,经常用于治疗高血压和某些心血管疾病,其特征是能够通过抑制三联苯胺对心脏和血管血管的影响来降低血压,导致心率和血管抗药性下降.盐酸甲醇通常以盐的形式施用,这增加了其溶性与生物利用率.该化合物已知具有中度半衰期,允许有效的剂量疗法.在安全和副作用方面,它可能造成典型的阻塞性反应,如疲劳,眩晕或心肌炎.与许多药品一样,它的使用应当由保健专业人员加以监测,以便有效地管理潜在的相互作用和抗药性.
- 英文名称Arotinolol Hcl
- 中文名称盐酸阿罗洛尔
- IUPAC名称2-Thiophenecarboxamide, 5-(2-((3-((1,1-dimethylethyl)amino)-2-hydroxypropyl)thio)-4-thiazolyl)-, monohydrochloride, (+-)-
- 其它别名AROTINOLOL HCL; AROTINOLOL HYDR°CHLORIDE; (+-)-2-(3’-tert-butylamino-2’-hydroxypropylthio)-4-(5’-carbamoyl-2’-thienyl); 2-thiophenecarboxamide,5-(2-((3-((1,1-dimethylethyl)amino)-2-hydroxypropyl)thi; monohydr°Chloride,(+-)-o)-4-thiazolyl); thiazolehcl; 2-Thiophenecarboxamide, 5-[2-[[3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl]thio]-4-thiazolyl]-, monohydr°Chloride
- CAS编号68377-91-3
- MFCD编号:MFCD00941421
- EINECS号:818-190-6
- FDA UNII编号:9DOI1HT306
- 分子式:C15H22ClN3O2S3分子量:408.0
- 产品CID: 1673892
- 同类组份化合物CAS68377-92-4 (free base)68377-91-3 (HCl)87055-50-3 (R-isomer HCl)92075-58-6 (R-isomer)101540-26-5 (S-isomer HCl)
- 产品分类原料药 → 循环系统用药 → 抗心律失常药
物理性质
MSDS等安全信息
欧盟法规
C&L通报上下游产品
tert-butylaminetert-butylamine 5-(2-mercapto-1,3-thiazol-4-yl)-2-thiophene carboxamide arotinolol 5-acetylthiophene-2-carboxylic acid合成工艺路线路线简述
海关参考信息
- 2905122000-异丙醇
2912110000-甲醛
2922110001-单乙醇胺
2921199090-其他无环单胺 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Wang Z, Zhang X, Jiang S, Guo X. Magnetic solid-phase extraction based on magnetic multiwalled carbon nanotubes for the simultaneous enantiomeric analysis of five β-blockers in the environmental samples by chiral liquid chromatography coupled with tandem mass spectrometry. Talanta. 2018 Apr 1;180:98-107. doi: 10.1016/j.talanta.2017.12.034. Epub 2017 Dec 14. doi: 10.1002/jssc.201700784. Epub 2017 Dec 11. doi: 10.1002/bmc.3991. Epub 2017 May 28. doi: 10.1016/j.parkreldis.2016.04.021. Epub 2016 Apr 21. doi: 10.1055/s-0035-1549931. Epub 2015 May 13. doi: 10.1159/000377671. eCollection 2015 Jan-Apr.
7: Qian Z, Xu Y, Zheng L, Zhang J, Hong Z, Shen X. Enantiospecific determination of arotinolol in rat plasma by LC-MS/MS: application to a stereoselective pharmacokinetic study. J Pharm Biomed Anal. 2015 Jan;102:299-304. doi: 10.1016/j.jpba.2014.09.034. Epub 2014 Oct 2. doi: 10.1159/000360976. Epub 2014 Apr 11.
9: Fang H, Chen W, Liu X, Xu W. The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study. Clin Exp Hypertens. 2014;36(8):590-5. doi: 10.3109/10641963.2014.897714. Epub 2014 Mar 28. doi: 10.1371/journal.pone.0088722. eCollection 2014.
合成参考文献
摘要:Drugs of the Future., 4(442), 1979
摘要:Iyakuhin Kenkyu. Study of Medical Supplies., 17(365), 1986
参考文献:10.1186/s12876-021-01874-7
摘要:He Y, Qin MZ, Chen YW. Liver injury caused by fenofibrate within 48 h after first administration: a case report. BMC Gastroenterol. 2021 Jul 29;21(1):298.
📝 需求与反馈
尽可能描述清楚需求与问题信息
